UroGen Pharma announces publication of development program for ZUSDURI

UroGen Pharma (URGN) announced the publication of a comprehensive review of the clinical development program for ZUSDURI for intravesical solution, formerly known as UGN-102, the first and only FDA-approved medicine for adults with recurrent, low-grade, intermediate-risk non-muscle-invasive bladder cancer. The article titled: “Review of UGN-102: A Reverse Thermal Gel Containing Mitomycin for the Treatment of Recurrent, Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer” is published in the peer-reviewed journal Reviews in Urology, the official journal of LUGPA. High Complete Response Rates: Across late-stage clinical trials, UGN-102 demonstrated complete response rates between 64.8% and 79.6% at three months. Durable Disease Response: In the ENVISION trial, 80.6% of patients remained disease-free at 18 months following CR. Manageable Safety Profile: Adverse events were primarily localized to the lower urinary tract. No Adverse Impact from Patient-Reported Outcomes: Clinical trials show that ZUSDURI did not adversely affect functionality, symptom burden, and quality of life in patients with LG-IR-NMIBC.